A Phase I, Open-Label, Two-Arm Study of MP-424 [telaprevir] in Combination With Peginterferon Alfa 2b and Ribavirin in Patients With Genotype 1b Hepatitis C
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2014
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 17 Jan 2013 Actual initiation date changed from Jan 2008 to Apr 2008 as reported by ClinicalTrials.gov.
- 04 Sep 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 04 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.